Quick Answer: For a straightforward 510(k), FDA's own performance data shows an average total time to decision of roughly four months once your submission is filed, under its MDUFA V goal of a decision within 90 FDA days for 95% of submissions [1]. That number describes FDA's clock, not your total project timeline. For a Taiwanese manufacturer, three things typically add real time before FDA's clock even starts: building a defensible predicate case, since TFDA's own classification and Taiwan-market history carry no weight at FDA; assembling test data to FDA-recognized standard versions, even when the underlying testing was performed at a TAF-accredited lab; and completing US Agent and establishment registration logistics, which are distribution requirements, not submission requirements, but still take real setup time. TFDA is an MDSAP Affiliate Member, and a manufacturer that pursues a full MDSAP audit with FDA in scope can skip a separate FDA facility inspection entirely, which is the single biggest lever available for compressing the realistic end-to-end timeline.
FDA's clock, precisely
FDA's MDUFA V goal commits to a Substantive Interaction, the point where FDA sends its first round of questions, within 60 FDA days for 95% of submissions, and a full decision within 90 FDA days for 95% of submissions [1]. "FDA days" pause whenever the agency is waiting on you, most commonly during an Additional Information request, so the more useful planning number is the real, all-in average: FDA's own reporting shows total time to decision, in calendar days, running roughly 110 to 130 days across recent fiscal years [1]. That's the number to plan around for a submission that doesn't hit major complications, not the 90-day goal on its own.
Two things extend this meaningfully. An AI cycle, triggered by an incomplete predicate argument or missing test data, adds weeks each time, and there's no cap on how many cycles a review can generate. And in 2023, submissions began going through eSTAR, which runs a technical screening rather than the older Refuse to Accept process [4, 5]; a properly assembled eSTAR file generally clears this stage within about 15 calendar days, but an incomplete one restarts that clock. None of this changes FDA's published fees, which are fixed regardless of your timeline: a standard 510(k) is $28,653 in FY2027, or $7,163 with small business status [2].
Where Taiwanese manufacturers actually lose time
None of this is specific to nationality in a legal sense, but three patterns show up consistently for manufacturers coming from Taiwan's manufacturing base specifically.
Predicate search takes longer when your device wasn't originally built with the US market in mind Taiwan's device manufacturing strength runs heavily through electronics, precision instruments, and IVD components, often built first for domestic or regional markets. Choosing a defensible predicate is a US-specific exercise regardless of your TFDA classification or Taiwan sales history, and a device with a strong Taiwan or ASEAN track record can still turn up a thin or nonexistent predicate landscape in the US product code database. Finding this out during your predicate search, rather than after a submission, is the difference between a schedule slip and a full AI cycle.
Test data gets rebuilt, not reused, when standard versions or endpoints don't match TAF-accredited testing carries real, internationally recognized credibility. It doesn't automatically satisfy FDA if the standard version tested, or the specific endpoints covered, don't match what your predicate and product code require. Confirming this before you scope a submission, rather than during FDA's review, is the single most common place a timeline assumption breaks.
US Agent and establishment registration logistics get sequenced wrong These are conditions of commercial distribution, not of 510(k) submission or clearance, and manufacturers sometimes complete them early assuming they're a submission prerequisite. That's not a timeline risk to your FDA review directly, but it does mean a company sometimes discovers, mid-project, that a step it thought was already handled isn't actually required yet, or is required sooner than expected once clearance is close.
The MDSAP lever, used correctly
This is the most concrete, actionable piece of this whole timeline, and it's worth using deliberately rather than as an afterthought.
TFDA is an MDSAP Affiliate Member [3]. That status governs how TFDA itself uses MDSAP reports for its own domestic Quality System Documentation purposes, and it's a separate question from what MDSAP does for you at FDA. What matters for your FDA timeline is simpler: MDSAP audits the manufacturer, not the manufacturer's home regulator. Any manufacturer, including a Taiwanese one, can engage a recognized MDSAP Auditing Organization for an audit covering the requirements of the program's five full Members: Australia, Brazil, Canada, Japan, and the US. If FDA is included in that audit's scope, FDA accepts the resulting report as a substitute for its own routine surveillance inspection [3].
That's real time saved, not just administrative convenience. A facility inspection scheduled and conducted separately by FDA adds real calendar time to a clearance timeline, on top of everything else. A manufacturer that's already pursuing MDSAP for other market access reasons, which is common among Taiwan-based companies also serving Japan or Canada, should make sure FDA is explicitly included in scope from the start, rather than treating the FDA relevance as an afterthought once a US launch is already planned.
A realistic sequence, start to finish
| Stage | What happens | Realistic duration |
|---|---|---|
| Classification and predicate search | Confirm US product code independently of TFDA class; identify candidate predicates | Weeks to a few months, depending on predicate clarity |
| Gap analysis | Map existing TAF test reports and ISO 13485 documentation against predicate requirements | Weeks |
| Fill gaps and confirm MDSAP scope | Complete missing testing; decide whether to include FDA in an MDSAP audit | Highly variable; MDSAP audit lead time alone can run months |
| eSTAR submission | Assemble and file a complete package | 15 days to technical screening, if the file is complete |
| FDA substantive review | Review to decision, per MDUFA V goals and real averages | ~110-130 calendar days for a clean review [1] |
| US Agent and establishment registration | Complete ahead of commercial distribution | Timed to your launch date, not your submission date |
Best for: budgeting a first FDA submission from a standing start. A repeat filer with an established predicate and MDSAP audit already in place will move faster through the earlier stages.
A few of these stages are worth a closer look. Predicate search and classification should run in parallel, not sequentially, since a thin predicate result should change your pathway planning before it becomes a submission-deadline problem. Gap analysis means mapping what you already have against what your specific predicate and product code actually require, standard by standard, not assuming existing testing transfers wholesale. And if MDSAP is worth pursuing given your broader export plans, that's the point to schedule it, since the audit itself takes real lead time to arrange.
Common mistakes
Treating FDA's 90-day goal as the total project timeline. It's FDA's own review clock, measured in FDA days that pause during AI holds. Real elapsed time from submission to decision runs meaningfully longer even in a clean review.
Assuming TAF-accredited testing transfers automatically. It carries real credibility. Confirming the specific standard version and endpoints match FDA's requirements is a separate, necessary step.
Scoping MDSAP for domestic Taiwan or regional purposes without including FDA. If you're already planning an MDSAP audit for other reasons, the marginal cost of including FDA in scope is small relative to the FDA inspection time it can save later.
Starting the predicate search after testing is already scoped. A thin predicate landscape changes your pathway, and sometimes points toward De Novo instead of 510(k). Finding this early is a planning decision; finding it late is a schedule risk.
Registering a US establishment before there's a US buyer. It's a distribution requirement, not a submission requirement, and starts an annual fee for no immediate benefit.
Frequently asked questions
How long does FDA clearance take for a Taiwanese medical device manufacturer? For a straightforward 510(k) with a clear predicate, budget roughly four months for FDA's own review once the submission is filed, based on FDA's real average total time to decision. Add time before that for predicate research, gap analysis against your existing TAF testing, and any evidence gaps that need filling; a realistic end-to-end project timeline for a first-time filer often runs considerably longer than FDA's review time alone.
Does an MDSAP audit actually speed up FDA clearance for Taiwanese manufacturers? Yes, if FDA is explicitly included in the audit's scope. MDSAP audits the manufacturer, not TFDA, so a Taiwanese manufacturer can pursue a recognized MDSAP audit the same way any manufacturer can, and FDA accepts the resulting report as a substitute for its own routine facility inspection.
Is TFDA an MDSAP member? TFDA holds Affiliate Member status in MDSAP, per FDA's own program page. That status governs how TFDA itself uses MDSAP reports for Taiwan's domestic Quality System Documentation purposes. It's separate from whether FDA accepts an MDSAP audit for your facility, which depends on your own audit's scope, not TFDA's participation tier.
Does TAF-accredited testing save time in an FDA submission? It can, if the specific tests performed match the FDA-recognized standard version and endpoints your predicate and product code require. TAF accreditation is a genuine quality signal; it doesn't by itself guarantee the testing was scoped correctly for FDA's specific requirements.
What's the single biggest cause of delay for a first-time Taiwanese filer? Predicate uncertainty discovered late. A device with a strong track record in Taiwan or the wider region can still have a thin or unclear predicate landscape in the US market, which changes pathway planning if found early and causes real schedule slippage if found during FDA's review instead.
Do I need to complete US Agent registration before I submit my 510(k)? No. US Agent designation and establishment registration are conditions of commercial distribution in the United States, not of submitting or receiving a 510(k) clearance. Completing them too early starts an annual registration fee before you have anything to sell.
How many rounds of FDA questions should I expect? There's no fixed number. FDA's Substantive Interaction goal is 60 FDA days for 95% of submissions, and each Additional Information cycle after that adds real calendar time, since the clock pauses while FDA waits on your response. A submission with a well-supported predicate and complete evidence package generally sees fewer cycles than one built on assumptions.
Does eSTAR change the timeline? Yes, at the front end. Since October 2023, submissions go through eSTAR's technical screening rather than the older Refuse to Accept process, and a complete, correctly formatted submission generally clears this stage in about 15 calendar days. An incomplete one can be rejected back to the sponsor, restarting that portion of the clock.
Key takeaways
FDA's 90-day goal describes FDA's clock, not your project timeline. Real average total time to decision runs closer to four months, and that's before accounting for AI cycles or pre-submission work.
MDSAP, with FDA explicitly in scope, is the most concrete lever available. It substitutes for a separate FDA facility inspection, and it's available to any manufacturer regardless of TFDA's own Affiliate status.
Predicate uncertainty is the biggest real risk to a Taiwanese filer's timeline. Finding it early is a planning decision. Finding it during FDA's review is a schedule problem.
TAF testing is credible, not automatically sufficient. Confirming standard versions and endpoints against your specific predicate is a distinct, necessary step, not a formality.
Sequence US Agent and establishment registration to your distribution date, not your submission date. They're separate requirements with separate timing.
Complizen helps international medical device manufacturers reach FDA 510(k) clearance, combining a software platform for in-house regulatory teams with full-service consultancy for teams without in-house FDA expertise.
Building a realistic timeline starts with an honest predicate and evidence-gap assessment, not an assumption based on your TFDA file. Complizen's free Gap Assessment maps your specific device against FDA's classification and predicate landscape in writing, with a realistic timeline estimate included. Request your Gap Assessment →
References
- FDA — MDUFA Performance Goals and Procedures, Fiscal Years 2023 Through 2027. https://www.fda.gov/media/73507/download
- Federal Register — Medical Device User Fee Rates for Fiscal Year 2027. https://www.federalregister.gov/documents/2026/07/30/2026-15335/medical-device-user-fee-rates-for-fiscal-year-2027
- FDA — Medical Device Single Audit Program (MDSAP). https://www.fda.gov/medical-devices/cdrh-international-affairs/medical-device-single-audit-program-mdsap
- FDA — 510(k) Submission Process. https://www.fda.gov/medical-devices/premarket-notification-510k/510k-submission-process
- FDA — eSTAR Program. https://www.fda.gov/medical-devices/how-study-and-market-your-device/estar-program
- Taiwan Accreditation Foundation (TAF) — ISO/IEC 17025 Testing Laboratory accreditation programme. https://www.taftw.org.tw/en/getting-accredited/field/